CliffBio
small molecule

BREXPIPRAZOLE

BREXPIPRAZOLE

Loss of exclusivity—loss of exclusivity
CompanyLupin →See this company's full patent-cliff portfolio

Drug detail

Brand nameBREXPIPRAZOLE
Active ingredientBREXPIPRAZOLE
Strength0.25MG
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalMarch 2023
Marketing statusDISCN

More from Lupin

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.